Pregnane X receptor and human malignancy

Histology and Histopathology

Volumn 28, Issue 4, 2013, Pages 405-420

  Koutsounas, Ioannis ^a   Patsouris, Efstratios ^a   Theocharis, Stamatios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cancer; Drug drug interactions; Metabolism; Pregnane X receptor; Xenobiotics

Indexed keywords

ANTINEOPLASTIC AGENT; LIGAND; PREGNANE X RECEPTOR; STEROID RECEPTOR;

ANIMAL; DRUG EFFECT; DRUG INTERACTION; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; NEOPLASM; PATHOLOGY; PROGNOSIS; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG INTERACTIONS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LIGANDS; NEOPLASMS; PROGNOSIS; RECEPTORS, STEROID; SIGNAL TRANSDUCTION;

EID: 84876450165     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (106)

1. Albermann N., Schmitz-Winnenthal F.H., Z'Graggen K., Volk C., Hoffmann M.M., Haefeli W.E. and Weiss J. (2005). Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem. Pharmacol. 70, 949-958.
2. Andersen V., Christensen J., Overvad K., Tjonneland A. and Vogel U. (2010). Polymorphisms in NFkB, PXR, LXR and risk of colorectal cancer in a prospective study of Danes. BMC Cancer 10, 484.
3. Backman J.T., Olkkola K.T. and Neuvonen P.J. (1996). Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin. Pharmacol. Ther. 59, 7-13.
4. Baker D.K., Relling M.V., Pui C.H., Christensen M.L., Evans W.E. and Rodman J.H. (1992). Increased teniposide clearance with concomitant anticonvulsant therapy. J. Clin. Oncol. 10, 311-315.
5. Beral V. (2003). Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362, 419-427.
6. Bolton A.E., Peng B., Hubert M., Krebs-Brown A., Capdeville R., Keller U. and Seiberling M. (2004). Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother. Pharmacol. 53, 102-106.
7. Cerveny L., Svecova L., Anzenbacherova E., Vrzal R., Staud F., Dvorak Z., Ulrichova J., Anzenbacher P. and Pavek P. (2007). Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab. Dispos. 35, 1032-1041.
8. Chang T.K., Yu L., Maurel P. and Waxman D.J. (1997). Enhanced cyclophosphamide and ifosfamide activation in primary human hepatocyte cultures: response to cytochrome P-450 inducers and autoinduction by oxazaphosphorines. Cancer Res. 57, 1946-1954.
9. Chang S.M., Kuhn J.G., Rizzo J., Robins H.I., Schold S.C. Jr., Spence A.M., Berger M.S., Mehta M.P., Bozik M.E., Pollack I., Gilbert M., Fulton D., Rankin C., Malec M. and Prados M.D. (1998). Phase I study of paclitaxel in patients with recurrent malignant glioma: a North American Brain Tumor Consortium report. J. Clin. Oncol. 16, 2188-2194.
10. Chen T. (2010). Overcoming drug resistance by regulating nuclear receptors. Adv. Drug Deliv. Rev. 62, 1257-1264.
11. Chen Y., Tang Y., Wang M.T., Zeng S. and Nie D. (2007). Human pregnane X receptor and resistance to chemotherapy in prostate cancer. Cancer Res. 67, 10361-10367.
12. Chen Y., Tang Y., Robbins G.T. and Nie D. (2010). Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor. J. Pharmacol. Exp. Ther. 334, 999-1008.
13. Choi H.K., Yang J.W., Roh S.H., Han C.Y. and Kang K.W. (2007). Induction of multidrug resistance associated protein 2 in tamoxifen-resistant breast cancer cells. Endocr. Relat. Cancer 14, 293-303.
14. Dai G., He L., Bu P. and Wan Y.J. (2008). Pregnane X receptor is essential for normal progression of liver regeneration. Hepatology 47, 1277-1287.
15. Desai P.B., Nallani S.C., Sane R.S., Moore L.B., Goodwin B.J., Buckley D.J. and Buckley A.R. (2002). Induction of cytochrome P450 3A4 in primary human hepatocytes and activation of the human pregnane X receptor by tamoxifen and 4-hydroxytamoxifen. Drug Metab. Dispos. 30, 608-612.
16. Desta Z., Ward B.A., Soukhova N.V. and Flockhart D.A. (2004). Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J. Pharmacol. Exp. Ther. 310, 1062-1075.
17. di Masi A., De Marinis E., Ascenzi P. and Marino M. (2009). Nuclear receptors CAR and PXR: Molecular, functional, and biomedical aspects. Mol. Aspects Med. 30, 297-343.
18. Dotzlaw H., Leygue E., Watson P. and Murphy L.C. (1999). The human orphan receptor PXR messenger RNA is expressed in both normal and neoplastic breast tissue. Clin. Cancer Res. 5, 2103-2107.
19. Dowsett M., Cuzick J., Howell A. and Jackson I. (2001). Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial. Br. J. Cancer 85, 317-324.
20. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S. and Sawyers C.L. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344, 1031-1037.
21. Gong H., Singh S.V., Singh S.P., Mu Y., Lee J.H., Saini S.P., Toma D., Ren S., Kagan V.E., Day B.W., Zimniak P. and Xie W. (2006). Orphan nuclear receptor pregnane X receptor sensitizes oxidative stress responses in transgenic mice and cancerous cells. Mol. Endocrinol. 20, 279-290.
22. Gupta E., Lestingi T.M., Mick R., Ramirez J., Vokes E.E. and Ratain M.J. (1994). Metabolic fate of irinotecan in humans: correlation of glucuronidation with diarrhea. Cancer Res. 54, 3723-3725.
23. Gupta A., Mugundu G.M., Desai P.B., Thummel K.E. and Unadkat J.D. (2008a). Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab. Dispos. 36, 1172-1180.
24. Gupta D., Venkatesh M., Wang H., Kim S., Sinz M., Goldberg G.L., Whitney K., Longley C. and Mani S. (2008b). Expanding the roles for pregnane X receptor in cancer: proliferation and drug resistance in ovarian cancer. Clin. Cancer Res. 14, 5332-5340.
25. Habano W., Gamo T., Terashima J., Sugai T., Otsuka K., Wakabayashi G. and Ozawa S. (2011). Involvement of promoter methylation in the regulation of Pregnane X receptor in colon cancer cells. BMC Cancer 11, 81.
26. Han Y. and Sugiyama Y. (2006). Expression and regulation of breast cancer resistance protein and multidrug resistance associated protein 2 in BALB/c mice. Biol. Pharm. Bull. 29, 1032-1035.
27. Harmsen S., Meijerman I., Beijnen J.H. and Schellens J.H. (2007). The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat. Rev. 33, 369-380.
28. Harmsen S., Meijerman I., Febus C.L., Maas-Bakker R.F., Beijnen J.H. and Schellens J.H. (2010). PXR-mediated induction of P-glycoprotein by anticancer drugs in a human colon adenocarcinoma-derived cell line. Cancer Chemother. Pharmacol. 66, 765-771.
29. Haughton E.L., Tucker S.J., Marek C.J., Durward E., Leel V., Bascal Z., Monaghan T., Koruth M., Collie-Duguid E., Mann D.A., Trim J.E. and Wright M.C. (2006). Pregnane X receptor activators inhibit human hepatic stellate cell transdifferentiation in vitro. Gastroenterology 131, 194-209.
30. Healan-Greenberg C., Waring J.F., Kempf D.J., Blomme E.A., Tirona R.G. and Kim R.B. (2008). A human immunodeficiency virus protease inhibitor is a novel functional inhibitor of human pregnane X receptor. Drug Metab. Dispos. 36, 500-507.
31. Honkakoski P., Sueyoshi T. and Negishi M. (2003). Drug-activated nuclear receptors CAR and PXR. Ann. Med. 35, 172-182.
32. Honorat M., Mesnier A., Di Pietro A., Lin V., Cohen P., Dumontet C. and Payen L. (2008). Dexamethasone down-regulates ABCG2 expression levels in breast cancer cells. Biochem. Biophys. Res. Commun. 375, 308-314.
33. Hor S.Y., Lee S.C., Wong C.I., Lim Y.W., Lim R.C., Wang L.Z., Fan L., Guo J.Y., Lee H.S., Goh B.C. and Tan T. (2008). PXR, CAR and HNF4alpha genotypes and their association with pharmacokinetics and pharmacodynamics of docetaxel and doxorubicin in Asian patients. Pharmacogenomics J. 8, 139-146.
34. Huang H., Wang H., Sinz M., Zoeckler M., Staudinger J., Redinbo M.R., Teotico D.G., Locker J., Kalpana G.V. and Mani S. (2007). Inhibition of drug metabolism by blocking the activation of nuclear receptors by ketoconazole. Oncogene 26, 258-268.
35. Huang R., Murry D.J., Kolwankar D., Hall S.D. and Foster D.R. (2006). Vincristine transcriptional regulation of efflux drug transporters in carcinoma cell lines. Biochem. Pharmacol. 71, 1695-1704.
36. Ivanovic J., Nicastri E., Ascenzi P., Bellagamba R., De Marinis E., Notari S., Pucillo L.P., Tozzi V., Ippolito G. and Narciso P. (2008). Therapeutic drug monitoring in the management of HIV-infected patients. Curr. Med. Chem. 15, 1925-1939.
37. Jiang H., Chen K., He J., Pan F., Li J., Chen J., Chen W. and Liang H. (2009). Association of pregnane X receptor with multidrug resistance-related protein 3 and its role in human colon cancer chemoresistance. J. Gastrointest. Surg. 13, 1831-1838.
38. Justenhoven C., Schaeffeler E., Winter S., Baisch C., Hamann U., Harth V., Rabstein S., Spickenheuer A., Pesch B., Bruning T., Ko Y.D., Schwab M. and Brauch H. (2011). Polymorphisms of the nuclear receptor pregnane X receptor and organic anion transporter polypeptides 1A2, 1B1, 1B3, and 2B1 are not associated with breast cancer risk. Breast Cancer Res. Treat. 125, 563-569.
39. Kerbusch T., Jansen R.L., Mathot R.A., Huitema A.D., Jansen M., van Rijswijk R.E. and Beijnen J.H. (2001). Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin. Clin. Pharmacol. Ther. 70, 132-141.
40. Konig J., Seithel A., Gradhand U. and Fromm M.F. (2006). Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch. Pharmacol. 372, 432-443.
41. Kuan C.Y., Walker T.H., Luo P.G. and Chen C.F. (2011). Long-chain polyunsaturated fatty acids promote paclitaxel cytotoxicity via inhibition of the MDR1 gene in the human colon cancer Caco-2 cell line. J. Am. Coll. Nutr. 30, 265-273.
42. Kublbeck J., Reinisalo M., Mustonen R. and Honkakoski P. (2010). Up-regulation of CYP expression in hepatoma cells stably transfected by chimeric nuclear receptors. Eur. J. Pharm. Sci. 40, 263-272.
43. Kumar S., Jaiswal B., Negi S. and Tyagi R.K. (2010). Cross-talk between androgen receptor and pregnane and xenobiotic receptor reveals existence of a novel modulatory action of anti-androgenic drugs. Biochem. Pharmacol. 80, 964-976.
44. Lamba V., Yasuda K., Lamba J.K., Assem M., Davila J., Strom S. and Schuetz E.G. (2004). PXR (NR1I2): splice variants in human tissues, including brain, and identification of neurosteroids and nicotine as PXR activators. Toxicol. Appl. Pharmacol. 199, 251-265.
45. Lee J.H., Zhou J. and Xie W. (2008). PXR and LXR in hepatic steatosis: a new dog and an old dog with new tricks. Mol. Pharm. 5, 60-66.
46. Legendre C., Hori T., Loyer P., Aninat C., Ishida S., Glaise D., Lucas-Clerc C., Boudjema K., Guguen-Guillouzo C., Corlu A. and Morel F. (2009). Drug-metabolising enzymes are down-regulated by hypoxia in differentiated human hepatoma HepaRG cells: HIF-1alpha involvement in CYP3A4 repression. Eur. J. Cancer 45, 2882-2892.
47. Lehmann J.M., McKee D.D., Watson M.A., Willson T.M., Moore J.T. and Kliewer S.A. (1998). The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. J. Clin. Invest. 102, 1016-1023.
48. Lemaire G., Mnif W., Pascussi J.M., Pillon A., Rabenoelina F., Fenet H., Gomez E., Casellas C., Nicolas J.C., Cavailles V., Duchesne M.J. and Balaguer P. (2006). Identification of new human pregnane X receptor ligands among pesticides using a stable reporter cell system. Toxicol. Sci. 91, 501-509.
49. Lim H.S., Ju Lee H., Seok Lee K., Sook Lee E., Jang I.J. and Ro J. (2007). Clinical implications of CYP2D6 genotypes predictive of tamoxifen pharmacokinetics in metastatic breast cancer. J. Clin. Oncol. 25, 3837-3845.
50. Ma X., Idle J.R. and Gonzalez F.J. (2008). The pregnane X receptor: from bench to bedside. Expert Opin. Drug Metab. Toxicol. 4, 895-908.
51. Maier A., Zimmermann C., Beglinger C., Drewe J. and Gutmann H. (2007). Effects of budesonide on P-glycoprotein expression in intestinal cell lines. Br. J. Pharmacol. 150, 361-368.
52. Malekshah O.M., Bahrami A.R., Afshari J.T., Mosaffa F. and Behravan J. (2011). Correlation between PXR and ABCG2 patterns of mRNA expression in a MCF7 breast carcinoma cell derivative upon induction by proinflammatory cytokines. DNA Cell Biol. 30, 25-31.
53. Mani S., Huang H., Sundarababu S., Liu W., Kalpana G., Smith A.B. and Horwitz S.B. (2005). Activation of the steroid and xenobiotic receptor (human pregnane X receptor) by nontaxane microtubule-stabilizing agents. Clin. Cancer Res. 11, 6359-6369.
54. Marek C.J., Tucker S.J., Konstantinou D.K., Elrick L.J., Haefner D., Sigalas C., Murray G.I., Goodwin B. and Wright M.C. (2005). Pregnenolone-16alpha-carbonitrile inhibits rodent liver fibrogenesis via PXR (pregnane X receptor)-dependent and PXR-independent mechanisms. Biochem. J. 387, 601-608.
55. MARIE-GENICA (2010). Polymorphisms in genes of the steroid receptor superfamily modify postmenopausal breast cancer risk associated with menopausal hormone therapy. Int. J. Cancer 126, 2935-2946.
56. Masuyama H., Hiramatsu Y., Kodama J. and Kudo T. (2003). Expression and potential roles of pregnane X receptor in endometrial cancer. J. Clin. Endocrinol. Metab. 88, 4446-4454.
57. Masuyama H., Suwaki N., Tateishi Y., Nakatsukasa H., Segawa T. and Hiramatsu Y. (2005). The pregnane X receptor regulates gene expression in a ligand-and promoter-selective fashion. Mol. Endocrinol. 19, 1170-1180.
58. Masuyama H., Nakatsukasa H., Takamoto N. and Hiramatsu Y. (2007). Down-regulation of pregnane X receptor contributes to cell growth inhibition and apoptosis by anticancer agents in endometrial cancer cells. Mol. Pharmacol. 72, 1045-1053.
59. Mensah-Osman E.J., Thomas D.G., Tabb M.M., Larios J.M., Hughes D.P., Giordano T.J., Lizyness M.L., Rae J.M., Blumberg B., Hollenberg P.F. and Baker L.H. (2007). Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer 109, 957-965.
60. Meyer zu Schwabedissen H.E., Tirona R.G., Yip C.S., Ho R.H. and Kim R.B. (2008). Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res. 68, 9338-9347.
61. Miyoshi Y., Ando A., Takamura Y., Taguchi T., Tamaki Y. and Noguchi S. (2002). Prediction of response to docetaxel by CYP3A4 mRNA expression in breast cancer tissues. Int. J. Cancer 97, 129-132.
62. Murakami Y., Tanaka T., Murakami H., Tsujimoto M., Ohtani H. and Sawada Y. (2006). Pharmacokinetic modelling of the interaction between St John's wort and ciclosporin A. Br. J. Clin. Pharmacol. 61, 671-676.
63. Murry D.J., Cherrick I., Salama V., Berg S., Bernstein M., Kuttesch N. and Blaney S.M. (2002). Influence of phenytoin on the disposition of irinotecan: a case report. J. Pediatr. Hematol. Oncol. 24, 130-133.
64. Nguyen A. and Bouscarel B. (2008). Bile acids and signal transduction: role in glucose homeostasis. Cell. Signal. 20, 2180-2197.
65. Niemi M., Backman J.T., Fromm M.F., Neuvonen P.J. and Kivisto K.T. (2003). Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42, 819-850.
66. Nittke T., Selig S., Kallay E. and Cross H.S. (2008). Nutritional calcium modulates colonic expression of vitamin D receptor and pregnane X receptor target genes. Mol. Nutr. Food Res. 52 (Suppl 1), S45-51.
67. Ouyang N., Ke S., Eagleton N., Xie Y., Chen G., Laffins B., Yao H., Zhou B. and Tian Y. (2010). Pregnane X receptor suppresses proliferation and tumourigenicity of colon cancer cells. Br. J. Cancer 102, 1753-1761.
68. Owen A., Chandler B., Back D.J. and Khoo S.H. (2004). Expression of pregnane-X-receptor transcript in peripheral blood mononuclear cells and correlation with MDR1 mRNA. Antivir. Ther. 9, 819-821.
69. Pascussi J.M., Robert A., Nguyen M., Walrant-Debray O., Garabedian M., Martin P., Pineau T., Saric J., Navarro F., Maurel P. and Vilarem M.J. (2005). Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J. Clin. Invest. 115, 177-186.
70. Persson K.P., Ekehed S., Otter C., Lutz E.S., McPheat J., Masimirembwa C.M. and Andersson T.B. (2006). Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans. Pharm. Res. 23, 56-69.
71. Quattrochi L.C. and Guzelian P.S. (2001). Cyp3A regulation: from pharmacology to nuclear receptors. Drug Metab. Dispos. 29, 615-622.
72. Raynal C., Pascussi J.M., Leguelinel G., Breuker C., Kantar J., Lallemant B., Poujol S., Bonnans C., Joubert D., Hollande F., Lumbroso S., Brouillet J.P. and Evrard A. (2010). Pregnane X Receptor (PXR) expression in colorectal cancer cells restricts irinotecan chemosensitivity through enhanced SN-38 glucuronidation. Mol. Cancer 9, 46.
73. Relling M.V., Pui C.H., Sandlund J.T., Rivera G.K., Hancock M.L., Boyett J.M., Schuetz E.G. and Evans W.E. (2000). Adverse effect of anticonvulsants on efficacy of chemotherapy for acute lymphoblastic leukaemia. Lancet 356, 285-290.
74. Robey R.W., Polgar O., Deeken J., To K.W. and Bates S.E. (2007). ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 26, 39-57.
75. Rosenfeld J.M., Vargas R. Jr, Xie W. and Evans R.M. (2003). Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. Mol. Endocrinol. 17, 1268-1282.
76. Ross J., Plummer S.M., Rode A., Scheer N., Bower C.C., Vogel O., Henderson C.J., Wolf C.R. and Elcombe C.R. (2010). Human constitutive androstane receptor (CAR) and pregnane X receptor (PXR) support the hypertrophic but not the hyperplastic response to the murine nongenotoxic hepatocarcinogens phenobarbital and chlordane in vivo. Toxicol. Sci. 116, 452-466.
77. Sandanaraj E., Lal S., Selvarajan V., Ooi L.L., Wong Z.W., Wong N.S., Ang P.C., Lee E.J. and Chowbay B. (2008). PXR pharmacogenetics: association of haplotypes with hepatic CYP3A4 and ABCB1 messenger RNA expression and doxorubicin clearance in Asian breast cancer patients. Clin. Cancer Res. 14, 7116-7126.
78. Shah I., Houck K., Judson R.S., Kavlock R.J., Martin M.T., Reif D.M., Wambaugh J. and Dix D.J. (2011). Using nuclear receptor activity to stratify hepatocarcinogens. PLoS One 6, e14584.
79. Shibayama Y., Ushinohama K., Ikeda R., Yoshikawa Y., Motoya T., Takeda Y. and Yamada K. (2006). Effect of methotrexate treatment on expression levels of multidrug resistance protein 2, breast cancer resistance protein and organic anion transporters Oat1, Oat2 and Oat3 in rats. Cancer Sci. 97, 1260-1266.
80. Spitzweg C. and Morris J.C. (2002). The sodium iodide symporter: its pathophysiological and therapeutic implications. Clin. Endocrinol. (Oxf) 57, 559-574.
81. Staudinger J.L., Ding X. and Lichti K. (2006). Pregnane X receptor and natural products: beyond drug-drug interactions. Expert Opin. Drug Metab. Toxicol. 2, 847-857.
82. Staudinger J.L., Goodwin B., Jones S.A., Hawkins-Brown D., MacKenzie K.I., LaTour A., Liu Y., Klaassen C.D., Brown K.K., Reinhard J., Willson T.M., Koller B.H. and Kliewer S.A. (2001). The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity. Proc. Natl. Acad. Sci. USA 98, 3369-3374.
83. Synold T.W., Dussault I. and Forman B.M. (2001). The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med. 7, 584-590.
84. Tabb M.M., Sun A., Zhou C., Grun F., Errandi J., Romero K., Pham H., Inoue S., Mallick S., Lin M., Forman B.M. and Blumberg B. (2003). Vitamin K2 regulation of bone homeostasis is mediated by the steroid and xenobiotic receptor SXR. J. Biol. Chem. 278, 43919-43927.
85. Tachibana S., Yoshinari K., Chikada T., Toriyabe T., Nagata K. and Yamazoe Y. (2009). Involvement of Vitamin D receptor in the intestinal induction of human ABCB1. Drug Metab. Dispos. 37, 1604-1610.
86. Tham L.S., Holford N.H., Hor S.Y., Tan T., Wang L., Lim R.C., Lee H.S., Lee S.C. and Goh B.C. (2007). Lack of association of single-nucleotide polymorphisms in pregnane X receptor, hepatic nuclear factor 4alpha, and constitutive androstane receptor with docetaxel pharmacokinetics. Clin. Cancer Res. 13, 7126-7132.
87. Timsit Y.E. and Negishi M. (2007). CAR and PXR: the xenobiotic-sensing receptors. Steroids 72, 231-246.
88. van de Winkel A., van Zoest K.P., van Dekken H., Moons L.M., Kuipers E.J. and van der Laan L.J. (2011). Differential expression of the nuclear receptors farnesoid X receptor (FXR) and pregnane X receptor (PXR) for grading dysplasia in patients with Barrett's oesophagus. Histopathology 58, 246-253.
89. Wahli W. (2008). A gut feeling of the PXR, PPAR and NF-kappaB connection. J. Intern. Med. 263, 613-619.
90. Wang H., Huang H., Li H., Teotico D.G., Sinz M., Baker S.D., Staudinger J., Kalpana G., Redinbo M.R. and Mani S. (2007). Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin. Cancer Res. 13, 2488-2495.
91. Wang H., Li H., Moore L.B., Johnson M.D., Maglich J.M., Goodwin B., Ittoop O.R., Wisely B., Creech K., Parks D.J., Collins J.L., Willson T.M., Kalpana G.V., Venkatesh M., Xie W., Cho S.Y., Roboz J., Redinbo M., Moore J.T. and Mani S. (2008a). The phytoestrogen coumestrol is a naturally occurring antagonist of the human pregnane X receptor. Mol. Endocrinol. 22, 838-857.
92. Wang T., Ma X., Krausz K.W., Idle J.R. and Gonzalez F.J. (2008b). Role of pregnane X receptor in control of all-trans retinoic acid (ATRA) metabolism and its potential contribution to ATRA resistance. J. Pharmacol. Exp. Ther. 324, 674-684.
93. Willhauck M.J., Okane D.J., Wunderlich N., Goke B. and Spitzweg C. (2011). Stimulation of retinoic acid-induced functional sodium iodide symporter (NIS) expression and cytotoxicity of (1)(3)(1)I by carbamazepine in breast cancer cells. Breast Cancer Res. Treat. 125, 377-386.
94. Xie Y., Ke S., Ouyang N., He J., Xie W., Bedford M.T. and Tian Y. (2009). Epigenetic regulation of transcriptional activity of pregnane X receptor by protein arginine methyltransferase 1. J. Biol. Chem. 284, 9199-9205.
95. Yamaguchi H., Hishinuma T., Endo N., Tsukamoto H., Kishikawa Y., Sato M., Murai Y., Hiratsuka M., Ito K., Okamura C., Yaegashi N., Suzuki N., Tomioka Y. and Goto J. (2006). Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer. Int. J. Gynecol. Cancer 16, 979-985.
96. Yeung E.Y., Sueyoshi T., Negishi M. and Chang T.K. (2008). Identification of Ginkgo biloba as a novel activator of pregnane X receptor. Drug Metab. Dispos. 36, 2270-2276.
97. Zamboni W.C., Gajjar A.J., Heideman R.L., Beijnen J.H., Rosing H., Houghton P.J. and Stewart C.F. (1998). Phenytoin alters the disposition of topotecan and N-desmethyl topotecan in a patient with medulloblastoma. Clin. Cancer Res. 4, 783-789.
98. Zelunka E.J. (2002). Intravenous cyclosporine-rifampin interaction in a pediatric bone marrow transplant recipient. Pharmacotherapy 22, 387-390.
99. Zhai Y., Pai H.V., Zhou J., Amico J.A., Vollmer R.R. and Xie W. (2007). Activation of pregnane X receptor disrupts glucocorticoid and mineralocorticoid homeostasis. Mol. Endocrinol. 21, 138-147.
100. Zhang B., Cheng Q., Ou Z., Lee J.H., Xu M., Kochhar U., Ren S., Huang M., Pflug B.R. and Xie W. (2010). Pregnane X receptor as a therapeutic target to inhibit androgen activity. Endocrinology 151, 5721-5729.
101. Zhang J., Kuehl P., Green E.D., Touchman J.W., Watkins P.B., Daly A., Hall S.D., Maurel P., Relling M., Brimer C., Yasuda K., Wrighton S.A., Hancock M., Kim R.B., Strom S., Thummel K., Russell C.G., Hudson J.R. Jr, Schuetz E.G. and Boguski M.S. (2001). The human pregnane x receptor: Genomic structure and identification and functional characterization of natural allelic variants. Pharmacogenetics 11, 555-572.
102. Zhou C., Tabb M.M., Nelson E.L., Grun F., Verma S., Sadatrafiei A., Lin M., Mallick S., Forman B.M., Thummel K.E. and Blumberg B. (2006). Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation. J. Clin. Invest. 116, 2280-2289.
103. Zhou C., Poulton E.J., Grun F., Bammler T.K., Blumberg B., Thummel K.E. and Eaton D.L. (2007). The dietary isothiocyanate sulforaphane is an antagonist of the human steroid and xenobiotic nuclear receptor. Mol. Pharmacol. 71, 220-229.
104. Zhou C., Verma S. and Blumberg B. (2009). The steroid and xenobiotic receptor (SXR), beyond xenobiotic metabolism. Nucl. Recept. Signal. 7, e001.
105. Zhou J., Liu M., Zhai Y. and Xie W. (2008). The antiapoptotic role of pregnane X receptor in human colon cancer cells. Mol. Endocrinol. 22, 868-880.
106. Zimmermann K., Wittman M.D., Saulnier M.G., Velaparthi U., Sang X., Frennesson D.B., Struzynski C., Seitz S.P., He L., Carboni J.M., Li A., Greer A.F., Gottardis M., Attar R.M., Yang Z., Balimane P., Discenza L.N., Lee F.Y., Sinz M., Kim S. and Vyas D. (2010). SAR of PXR transactivation in benzimidazole-based IGF-1R kinase inhibitors. Bioorg. Med. Chem. Lett. 20, 1744-1748.